| For: | Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol 2014; 20(40): 14821-14830 [PMID: 25356042 DOI: 10.3748/wjg.v20.i40.14821] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i40/14821.htm |
| Number | Citing Articles |
| 1 |
Saehyun Lee, Byung-Joon Ko, Younghoon Gong, Kyungdo Han, Anna Lee, Byoung-Duck Han, Yeo Joon Yoon, Siyoung Park, Jung-Hyun Kim, Christos S. Mantzoros. Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults. European Journal of Nutrition 2016; 55(1) doi: 10.1007/s00394-015-0851-z
|
| 2 |
Lorène J. Lebrun, Kaatje Lenaerts, Dorien Kiers, Jean-Paul Pais de Barros, Naig Le Guern, Jiri Plesnik, Charles Thomas, Thibaut Bourgeois, Cornelis H.C. Dejong, Matthijs Kox, Inca H.R. Hundscheid, Naim Akhtar Khan, Stéphane Mandard, Valérie Deckert, Peter Pickkers, Daniel J. Drucker, Laurent Lagrost, Jacques Grober. Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. Cell Reports 2017; 21(5) doi: 10.1016/j.celrep.2017.10.008
|
| 3 |
Mümin A. Erdoğan, Emin Taşkıran, Gürkan Yiğittürk, Oytun Erbaş, Dilek Taşkıran. The investigation of therapeutic potential of oxytocin and liraglutide on vincristine‐induced neuropathy in rats. Journal of Biochemical and Molecular Toxicology 2020; 34(1) doi: 10.1002/jbt.22415
|
| 4 |
Ian C. Garbarine, Amanda K. Walsh, Timothy M. Pawlik, Sabrena F. Noria, Jordan M. Cloyd. Hepatic adenoma regression after bariatric surgery: a case series and systematic review. Surgical Endoscopy 2026; 40(2) doi: 10.1007/s00464-025-12350-8
|
| 5 |
Giovanna Muscogiuri, Ralph A. DeFronzo, Amalia Gastaldelli, Jens J. Holst. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends in Endocrinology & Metabolism 2017; 28(2) doi: 10.1016/j.tem.2016.10.001
|
| 6 |
Olfa Khalifa, Sama Ayoub, Abdelilah Arredouani. Exploring the Putative Involvement of MALAT1 in Mediating the Beneficial Effect of Exendin-4 on Oleic Acid-Induced Lipid Accumulation in HepG2 Cells. Biomedicines 2025; 13(2) doi: 10.3390/biomedicines13020370
|
| 7 |
Eunüs S. Ali, Jin Hua, Claire H. Wilson, George A. Tallis, Fiona H. Zhou, Grigori Y. Rychkov, Greg J. Barritt. The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca 2+ signalling in steatotic hepatocytes. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2016; 1863(9) doi: 10.1016/j.bbamcr.2016.05.006
|
| 8 |
Xiangjin Xu, Lu Lin, Pin Chen, Yunjie Yu, Shengping Chen, Xiangqi Chen, Zhulin Shao. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Research and Clinical Practice 2019; 150 doi: 10.1016/j.diabres.2019.03.002
|
| 9 |
Polly Gupta, Rustam Ekbbal. Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of
Cardiac Inflammatory and Apoptosis Markers. Current Drug Research Reviews 2024; 16(3) doi: 10.2174/0125899775243787231103075804
|
| 10 |
Emmanuel Jacobo-Tovar, Andrea Medel-Sánchez, Cosette Durán-Castillo, Rodolfo Guardado-Mendoza. Insulin resistance in cancer risk and prognosis. Seminars in Cancer Biology 2025; 114 doi: 10.1016/j.semcancer.2025.06.006
|
| 11 |
Tomasz Charytoniuk, Krzysztof Drygalski, Karolina Konstantynowicz-Nowicka, Klaudia Berk, Adrian Chabowski. Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. Nutrition 2017; 34 doi: 10.1016/j.nut.2016.09.001
|
| 12 |
Andreas Melidonis, Athanasia Papazafeiropoulou, Eleni-Margarita Tzouganatou, Eleni Xourgia. Anti-inflammatory properties of antidiabetic agents. World Journal of Meta-Analysis 2019; 7(4): 129-141 doi: 10.13105/wjma.v7.i4.129
|
| 13 |
Lyudmila V. Nedosugova, Yuliya V. Markina, Leyla A. Bochkareva, Irina A. Kuzina, Nina A. Petunina, Irina Y. Yudina, Tatiana V. Kirichenko. Inflammatory Mechanisms of Diabetes and Its Vascular Complications. Biomedicines 2022; 10(5) doi: 10.3390/biomedicines10051168
|
| 14 |
Tsukasa Kuriyama, Chisaki Ishibashi, Junji Kozawa, Megu Y. Baden, Tomomi Horii, Akiko Niki, Harutoshi Ozawa, Yoshiya Hosokawa, Yukari Fujita, Katsuhiko Sadahiro, Tomomi Satoh, Tomoya Hamaguchi, Iichiro Shimomura. Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes. Clinical Nutrition ESPEN 2024; 59 doi: 10.1016/j.clnesp.2023.12.005
|
| 15 |
Yoon Oh, Hee-Sook Jun. Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling. International Journal of Molecular Sciences 2017; 19(1) doi: 10.3390/ijms19010026
|
| 16 |
Ryan A. Lafferty, Finbarr P. M. O’Harte, Nigel Irwin, Victor A. Gault, Peter R. Flatt. Proglucagon-Derived Peptides as Therapeutics. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.689678
|
| 17 |
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, Durga Lohana, Parkash Kumar, Savitri Aninditha Nandula, Fatima Kausar Nawaz, Kevin Tracey, Huan Yang, Derek LeRoith, Michael J. Brownstein, Jesse Roth. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1148209
|
| 18 |
Ernest A. Adeghate. GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients. Expert Opinion on Pharmacotherapy 2024; 25(3) doi: 10.1080/14656566.2024.2328796
|
| 19 |
Vidhi Singh, Minhao Wang, Joseph Ebinger, Amanda Velazquez, Susan Cheng, Alan C. Kwan, Hirsh D. Trivedi. Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis. Journal of Clinical Gastroenterology 2026; doi: 10.1097/MCG.0000000000002396
|
| 20 |
Nabeel R Ahmed, Vaishnavi Vijaya Kulkarni, Sushil Pokhrel, Hamna Akram, Arowa Abdelgadir, Abanti Chatterjee, Safeera Khan. Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. Cureus 2022; doi: 10.7759/cureus.24829
|
| 21 |
Filippo Leggieri, Simon N. van Laarhoven, Vicente J. León Muñoz, Joaquin Moya-Angeler, Mustafa Akkaya, Roberto Civinini, Matteo Innocenti. No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty. Journal of Bone and Joint Surgery 2026; 108(9) doi: 10.2106/JBJS.25.00879
|
| 22 |
Philip N. Newsome, Phil Ambery. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. Journal of Hepatology 2023; 79(6) doi: 10.1016/j.jhep.2023.07.033
|
| 23 |
Zifeng Yang, Ruifeng Tian, Xiao-Jing Zhang, Jingjing Cai, Zhi-Gang She, Hongliang Li. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Frontiers in Cardiovascular Medicine 2023; 9 doi: 10.3389/fcvm.2022.1120085
|
| 24 |
Devaraj Ezhilarasan. Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?. Journal of Gastroenterology and Hepatology 2025; 40(9) doi: 10.1111/jgh.17037
|
| 25 |
Enrique Gallego-Colon, Wojciech Wojakowski, Tomasz Francuz. Incretin drugs as modulators of atherosclerosis. Atherosclerosis 2018; 278 doi: 10.1016/j.atherosclerosis.2018.09.011
|
| 26 |
Yousaf Zafar, Ahmed Mustafa Rashid, Ahmed Kamal Siddiqi, Aayat Ellahi, Aymen Ahmed, Hassan ul Hussain, Furqan Ahmed, Ritesh G. Menezes, Tariq Jamal Siddiqi, Muhammad Talha Maniya. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2022; 46(7) doi: 10.1016/j.clinre.2022.101970
|
| 27 |
Yunzhi Chen, Xuemei Yan, Xiao Xu, Shuhua Yuan, Fen Xu, Hua Liang. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide. Endocrine 2020; 70(3) doi: 10.1007/s12020-020-02470-7
|
| 28 |
Anna Vanderheiden, Lindsay B. Harrison, Jeremy T. Warshauer, Beverley Adams-Huet, Xilong Li, Qing Yuan, Keith Hulsey, Ivan Dimitrov, Takeshi Yokoo, Adam W. Jaster, Daniella F. Pinho, Ivan Pedrosa, Robert E. Lenkinski, Laurentiu M. Pop, Ildiko Lingvay. Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. The Journal of Clinical Endocrinology & Metabolism 2016; 101(4) doi: 10.1210/jc.2015-3906
|
| 29 |
Mai Salah Nour, Zeinab Abd El-Hay Sakara, Nawal Awad Hasanin, Shereen Mohamed Hamed. Histological and immunohistochemical study of the effect of liraglutide in experimental model of non-alcoholic fatty liver disease. Egyptian Journal of Basic and Applied Sciences 2023; 10(1) doi: 10.1080/2314808X.2023.2204258
|
| 30 |
Magdalena Rutkowska, Monika A. Olszewska. Anti-Diabetic Potential of Polyphenol-Rich Fruits from the Maleae Tribe—A Review of In Vitro and In Vivo Animal and Human Trials. Nutrients 2023; 15(17) doi: 10.3390/nu15173756
|
| 31 |
Ides M. Colin, Henri Colin, Ines Dufour, Charles‐Edouard Gielen, Marie‐Christine Many, Jean Saey, Bernard Knoops, Anne‐Catherine Gérard. Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR). Physiological Reports 2016; 4(15) doi: 10.14814/phy2.12886
|
| 32 |
Emmanouil Sinakos, Maria Kalogirou. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?. World Journal of Hepatology 2018; 10(11): 790-794 doi: 10.4254/wjh.v10.i11.790
|
| 33 |
Sayantan Ray, Partha Pal, Subhodip Pramanik. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies. World Journal of Methodology 2024; 14(2): 91319 doi: 10.5662/wjm.v14.i2.91319
|
| 34 |
Alexander Myint. Improvement of liver function and glycemic control with Combination of DPP-4 inhibitors and GLP-1 agonists in type II diabetes mellitus patients with non-alcoholic steatohepatitis. Gastroenterology & Hepatology: Open Access 2020; 11(3) doi: 10.15406/ghoa.2020.11.00427
|
| 35 |
Luigi Barrea, Carolina Di Somma, Giovanna Muscogiuri, Giovanni Tarantino, Gian Carlo Tenore, Francesco Orio, Annamaria Colao, Silvia Savastano. Nutrition, inflammation and liver-spleen axis. Critical Reviews in Food Science and Nutrition 2018; 58(18) doi: 10.1080/10408398.2017.1353479
|
| 36 |
Konstantin Kazankov, Simon Mark Dahl Jørgensen, Karen Louise Thomsen, Holger Jon Møller, Hendrik Vilstrup, Jacob George, Detlef Schuppan, Henning Grønbæk. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature Reviews Gastroenterology & Hepatology 2019; 16(3) doi: 10.1038/s41575-018-0082-x
|
| 37 |
Chien-Yu Lin, Pratik Adhikary, Kun Cheng. Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis. Advanced Drug Delivery Reviews 2021; 174 doi: 10.1016/j.addr.2021.04.008
|
| 38 |
Tao Hao, Hongying Chen, Sisi Wu, Haoming Tian. LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet. Molecular Medicine Reports 2019; doi: 10.3892/mmr.2019.10304
|
| 39 |
Derek M. Erion, Hyun-Jun Park, Hui-Young Lee. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Reports 2016; 49(3) doi: 10.5483/BMBRep.2016.49.3.268
|
| 40 |
Jordan Rowlands, Julian Heng, Philip Newsholme, Rodrigo Carlessi. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00672
|
| 41 |
Soo Lim, Soo Myoung Shin, Ga Eun Nam, Chang Hee Jung, Bo Kyung Koo. Proper Management of People with Obesity during the COVID-19 Pandemic. Journal of Obesity & Metabolic Syndrome 2020; 29(2) doi: 10.7570/jomes20056
|
| 42 |
Indyaswan T. Suryaningtyas, Won-Kyo Jung, Sei-Jung Lee, Jae-Young Je. Bioactive peptides PIISVYWK and FSVVPSPK improve glucose homeostasis by targeting DPP-IV and glucose transport in type 2 diabetic mice. International Immunopharmacology 2025; 158 doi: 10.1016/j.intimp.2025.114844
|
| 43 |
Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 2022; 11(6) doi: 10.3390/antiox11061060
|
| 44 |
Yinghui Zhang, Jia Guo, Yongchao Li, Kai Jiao, Yingbo Zhang. let-7a suppresses liver fibrosis via TGFβ/SMAD signaling transduction pathway. Experimental and Therapeutic Medicine 2019; doi: 10.3892/etm.2019.7457
|
| 45 |
Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Ignatios Ikonomidis. The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. Journal of Clinical Medicine 2025; 14(2) doi: 10.3390/jcm14020428
|
| 46 |
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment. Ageing Research Reviews 2024; 93 doi: 10.1016/j.arr.2023.102134
|
| 47 |
Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-01931-z
|
| 48 |
Menglei Shi, Sisi Chen, Yutong Feng, Shiyuan Wang, Yuyu Xia, Jianlin He. Marine natural products as an important source of bioactive substances for non-alcoholic fatty liver disease management. Frontiers in Marine Science 2025; 11 doi: 10.3389/fmars.2024.1523246
|
| 49 |
Honghong Liu, Jiawen Zheng, Taijing Zheng, Ping Wang. Exendin-4 regulates Wnt and NF-κB signaling in lipopolysaccharide-induced human periodontal ligament stem cells to promote osteogenic differentiation. International Immunopharmacology 2019; 75 doi: 10.1016/j.intimp.2019.105801
|
| 50 |
Hisanori Goto, Toshinari Takamura. Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies. Journal of Obesity & Metabolic Syndrome 2025; 34(3) doi: 10.7570/jomes25017
|
| 51 |
Yanyan Liu, Shin‐Ichi Harashima, Yu Wang, Kazuyo Suzuki, Shinsuke Tokumoto, Ryota Usui, Hisato Tatsuoka, Daisuke Tanaka, Daisuke Yabe, Norio Harada, Yoshitaka Hayashi, Nobuya Inagaki. Sphingosine kinase 1–interacting protein is a dual regulator of insulin and incretin secretion. The FASEB Journal 2019; 33(5) doi: 10.1096/fj.201801783RR
|
| 52 |
Salvatore Petta, KyeongJin Kim, Giovanni Targher, Stefano Romeo, Silvia Sookoian, Ming‐Hua Zheng, Alessio Aghemo, Luca Valenti. Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis. Liver International 2025; 45(11) doi: 10.1111/liv.70407
|
| 53 |
Ali A Rizvi, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Antonella Amato, Noor Al-Busaidi, Khalid Al-Rasadi, Maurizio Soresi, Maciej Banach, Giuseppe Montalto, Manfredi Rizzo. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opinion on Biological Therapy 2015; 15(10) doi: 10.1517/14712598.2015.1067299
|
| 54 |
Young-Sun Lee, Hee-Sook Jun. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediators of Inflammation 2016; 2016 doi: 10.1155/2016/3094642
|
| 55 |
Sonal Kumar, John E. Anderson, Andrea Coviello, Francisco Lopez-Jimenez, George L. Bakris. The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome. JACC: Advances 2026; 5(1) doi: 10.1016/j.jacadv.2025.102465
|
| 56 |
Mingjun Zou, Changli Liu. Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome 2026; 18(1) doi: 10.1186/s13098-026-02179-z
|
| 57 |
Na Ao, Jing Yang, Xiaochen Wang, Jian Du. Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway. Hepatology Research 2016; 46(4) doi: 10.1111/hepr.12551
|
| 58 |
Lawrence B. Afrin, Leonard B. Weinstock, Tania T. Dempsey, Katja Aschenbrenner, Svetlana Blitshteyn, Jill R. Schofield. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. The American Journal of the Medical Sciences 2025; 370(4) doi: 10.1016/j.amjms.2025.07.006
|
| 59 |
Tamara Zietek, Eva Rath. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Frontiers in Immunology 2016; 7 doi: 10.3389/fimmu.2016.00154
|
| 60 |
Maja Cigrovski Berkovic, Tanja Rezic, Ines Bilic-Curcic, Anna Mrzljak. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases 2022; 10(20): 6759-6768 doi: 10.12998/wjcc.v10.i20.6759
|
| 61 |
Fátima Higuera-de la Tijera, Alfredo I Servín-Caamaño. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World Journal of Hepatology 2015; 7(10): 1297-1301 doi: 10.4254/wjh.v7.i10.1297
|
| 62 |
Anastassia Amaro, Danny Sugimoto, Sean Wharton. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate Medicine 2022; 134(sup1) doi: 10.1080/00325481.2022.2147326
|
| 63 |
Chih-Ping Lin, Chi-Hsiang Chung, Chieh-Hua Lu, Sheng-Chiang Su, Feng-Chih Kuo, Jhih-Syuan Liu, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Chun-Yung Chang, Ming-Shiun Lin, Yi-Chen Liu, An-Che Cheng, Hong-Han Lin, Shi-Wen Kuo, Chien-Hsing Lee, Chang-Hsun Hsieh, Yi-Jen Hung, Hsin-Ya Liu, Lan-Yuen Guo, Wu-Chien Chien. Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study. Medicine 2025; 104(6) doi: 10.1097/MD.0000000000041243
|
| 64 |
Pin Chen, Lu Lin, Xiangjin Xu, Zhenting Zhang, Wei Cai, Zhulin Shao, Shengping Chen, Xiangqi Chen, Qiaoling Weng. Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin. Journal of Dermatological Treatment 2021; 32(7) doi: 10.1080/09546634.2019.1708853
|
| 65 |
Kathrin Kahnert, Tanja Lucke, Frank Biertz, Andreas Lechner, Henrik Watz, Peter Alter, Robert Bals, Jürgen Behr, Rolf Holle, Rudolf M. Huber, Stefan Karrasch, Beate Stubbe, Margarethe Wacker, Sandra Söhler, Emiel F. M. Wouters, Claus Vogelmeier, Rudolf A. Jörres. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respiratory Research 2017; 18(1) doi: 10.1186/s12931-016-0499-0
|
| 66 |
Yue Yao, Qiang Li, Ping Gao, Wei Wang, Lili Chen, Jinchao Zhang, Yi Xu. Glucagon-like peptide-1 contributes to increases ABCA1 expression by downregulating miR-758 to regulate cholesterol homeostasis. Biochemical and Biophysical Research Communications 2018; 497(2) doi: 10.1016/j.bbrc.2018.02.126
|
| 67 |
Chan-Hee Jung, Ji-Oh Mok. The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Journal of Obesity & Metabolic Syndrome 2019; 28(1) doi: 10.7570/jomes.2019.28.1.18
|
| 68 |
Xingchun Wang, Bingwei Ma, Jiaqi Chen, Hui You, Chunjun Sheng, Peng Yang, Shen Qu, Vito Angelo Giagulli. Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice. International Journal of Endocrinology 2021; 2021 doi: 10.1155/2021/6620289
|
| 69 |
Rhema Khairnar, Md Asrarul Islam, Joshua Fleishman, Sunil Kumar. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sciences 2023; 312 doi: 10.1016/j.lfs.2022.121185
|
| 70 |
Yifan Ren, Yuzhang Chen, Wenbin Zheng, Wen Kong, Yunfei Liao, Jiaoyue Zhang, Meng Wang, Tianshu Zeng. The effect of GLP‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 2025; 27(7) doi: 10.1111/dom.16366
|
| 71 |
Rosario Caltabiano, Daniele Condorelli, Salvatore Panza, Carla Boitani, Nicolò Musso, Davor Ježek, Lorenzo Memeo, Lorenzo Colarossi, Vittoria Rago, Valentina Mularoni, Saveria Spadola, Roberto Castiglione, Marta Santoro, Saveria Aquila, Rosario D'Agata. Glucagon‐like peptide‐1 receptor is expressed in human and rodent testis. Andrology 2020; 8(6) doi: 10.1111/andr.12871
|
| 72 |
Paula Luque-Linero, Luis Castilla-Guerra. Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting. European Cardiology Review 2024; 19 doi: 10.15420/ecr.2023.19
|
| 73 |
Xiao-Jiao Zhang, Xiao-Wei Han, Yan-Hui Jiang, Ya-Le Wang, Xing-Ling He, Dong-Hua Liu, Jie Huang, Hao-Hui Liu, Tao-Chun Ye, Si-Jing Li, Zi-Ru Li, Xiao-Ming Dong, Hong-Yan Wu, Wen-Jie Long, Shi-Hao Ni, Lu Lu, Zhong-Qi Yang. Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: From fundamental research to therapy. International Immunopharmacology 2023; 123 doi: 10.1016/j.intimp.2023.110747
|
| 74 |
Panagiotis Theofilis, Marios Sagris, Evangelos Oikonomou, Alexios S. Antonopoulos, Gerasimos Siasos, Kostas Tsioufis, Dimitris Tousoulis. The Anti-Inflammatory Effect of Novel Antidiabetic Agents. Life 2022; 12(11) doi: 10.3390/life12111829
|
| 75 |
Oleksandr Halushko, Natalia Bobok. Glucagon-like peptide-1 receptor agonists: prospects for use in the treatment of age-related diseases and aging. Problems of ageing and longevity (Ukraine) 2025; 30(4) doi: 10.71012/pro-ageing-2025-4-05
|
| 76 |
Jong Yeon Kang, Mikyung Kim, Yuna Kang, Wonmok Lee, Tae Kyung Ha, Ji Hae Seo, Young Gil Son, Eunyoung Ha. Thyroidectomy stimulates glucagon-like peptide-1 secretion and attenuates hepatic steatosis in high-fat fed rats. Biochemical and Biophysical Research Communications 2017; 493(1) doi: 10.1016/j.bbrc.2017.08.154
|
| 77 |
Rebecca K. Vincent, David M. Williams, Marc Evans. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?. Diabetes, Obesity and Metabolism 2020; 22(12) doi: 10.1111/dom.14196
|
| 78 |
Guizhen Chang, Baojiang Chen, Litao Zhang. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. Journal of Dermatological Treatment 2022; 33(3) doi: 10.1080/09546634.2021.1882658
|
| 79 |
Yolanda Diz-Chaves, Zainab Mastoor, Carlos Spuch, Lucas C. González-Matías, Federico Mallo. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International Journal of Molecular Sciences 2022; 23(17) doi: 10.3390/ijms23179583
|
| 80 |
Zachary Bloomgarden. Non‐alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control. Journal of Diabetes 2017; 9(8) doi: 10.1111/1753-0407.12566
|
| 81 |
Eleni Xourgia, Athanasia Papazafiropoulou, Andreas Melidonis. Effects of antidiabetic drugs on epicardial fat. World Journal of Diabetes 2018; 9(9): 141-148 doi: 10.4239/wjd.v9.i9.141
|
| 82 |
Manisha Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives. Life Sciences 2024; 353 doi: 10.1016/j.lfs.2024.122934
|
| 83 |
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022; 10(2) doi: 10.3390/biomedicines10020274
|
| 84 |
Emir Muzurović, Niki Katsiki, Špela Volčanšek, Fulvio Plescia, Manfredi Rizzo, Christos S. Mantzoros. Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism 2026; 177 doi: 10.1016/j.metabol.2026.156494
|
| 85 |
Tea Lund Laursen, Anders Mellemkjær, Holger Jon Møller, Henning Grønbæk, Konstantin Kazankov. Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 2022; 26(8) doi: 10.1080/14728222.2022.2132145
|
| 86 |
Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, Aranka Brockmueller, Mehdi Shakibaei, Dietrich Büsselberg. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer and Metastasis Reviews 2024; 43(4) doi: 10.1007/s10555-024-10192-9
|
| 87 |
Basile Njei, Yazan Al-Ajlouni, Samira Y Lemos, Derek Ugwendum, Prince Ameyaw, Lea-Pearl Njei, Sarpong Boateng. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 2024; doi: 10.7759/cureus.71366
|
| 88 |
Fernanda Cristina de Mesquita, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Raquel Maeso-Díaz, Sergi Vila, Diana Hide, Martí Ortega-Ribera, José Luís Rosa, Juan Carlos García-Pagán, Jaime Bosch, Jarbas Rodrigues de Oliveira, Jordi Gracia-Sancho. Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-02866-y
|
| 89 |
Xu Tao, Sruthi Ranganathan, Nicholas Van Halm-Lutterodt, Julia Garcia-Vargas, Andrew Wu, Janesh Karnati, Sachin Shankar, Nana Agyeman, Ahmed Ashraf, Parikshit Barve, Kelly Childress, Owoicho Adogwa. No Difference in Short-term Surgical Outcomes From Semaglutide Treatment for Type 2 Diabetes Mellitus After Cervical Decompression and Fusion. Spine 2025; 50(8) doi: 10.1097/BRS.0000000000005099
|
| 90 |
Naga S. Betrapally, Patrick M. Gillevet, Jasmohan S. Bajaj. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?. Gastroenterology 2016; 150(8) doi: 10.1053/j.gastro.2016.02.073
|
| 91 |
Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Manash Pratim Baruah, Mangesh Tiwaskar, Sambit Das, Sudip Chatterjee, Banshi Saboo, Ganapathi Bantwal, Saptarshi Bhattacharya, Gagan Priya, Manoj Chawla, Kiraninder Brar, Syed Abbas Raza, Azizul Hasan Aamir, Dina Shrestha, Noel Somasundaram, Prasad Katulanda, Faria Afsana, Shahjada Selim, Mohammad Wali Naseri, Ali Latheef, Manilka Sumanatilleke. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Therapy 2019; 10(5) doi: 10.1007/s13300-019-0669-4
|
| 92 |
John A. Dougherty, Erenie Guirguis, Krisy-Ann Thornby. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Annals of Pharmacotherapy 2021; 55(1) doi: 10.1177/1060028020935105
|